PL2373691T3 - PRZECIWCIAŁA ANTY-fXI I SPOSOBY ZASTOSOWANIA - Google Patents
PRZECIWCIAŁA ANTY-fXI I SPOSOBY ZASTOSOWANIAInfo
- Publication number
- PL2373691T3 PL2373691T3 PL09837993T PL09837993T PL2373691T3 PL 2373691 T3 PL2373691 T3 PL 2373691T3 PL 09837993 T PL09837993 T PL 09837993T PL 09837993 T PL09837993 T PL 09837993T PL 2373691 T3 PL2373691 T3 PL 2373691T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- fxi antibodies
- fxi
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13859008P | 2008-12-18 | 2008-12-18 | |
PCT/US2009/068768 WO2010080623A2 (en) | 2008-12-18 | 2009-12-18 | Anti-fxi antibodies and methods of use |
EP09837993.6A EP2373691B1 (en) | 2008-12-18 | 2009-12-18 | Anti-fxi antibodies and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2373691T3 true PL2373691T3 (pl) | 2019-07-31 |
Family
ID=42317079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL09837993T PL2373691T3 (pl) | 2008-12-18 | 2009-12-18 | PRZECIWCIAŁA ANTY-fXI I SPOSOBY ZASTOSOWANIA |
Country Status (15)
Country | Link |
---|---|
US (3) | US8388959B2 (pl) |
EP (1) | EP2373691B1 (pl) |
AU (1) | AU2009335643B2 (pl) |
CA (1) | CA2747519C (pl) |
CY (1) | CY1121562T1 (pl) |
DK (1) | DK2373691T3 (pl) |
ES (1) | ES2720594T3 (pl) |
HR (1) | HRP20190605T1 (pl) |
HU (1) | HUE042940T2 (pl) |
LT (1) | LT2373691T (pl) |
PL (1) | PL2373691T3 (pl) |
PT (1) | PT2373691T (pl) |
SI (1) | SI2373691T1 (pl) |
TR (1) | TR201904662T4 (pl) |
WO (1) | WO2010080623A2 (pl) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160046728A1 (en) * | 2007-10-31 | 2016-02-18 | Bioxodes Sa | Identification and molecular characterisation of proteins, expressed in the ixodes ricinus salivary glands |
AU2009335643B2 (en) * | 2008-12-18 | 2014-05-29 | Oregon Health & Science University | Anti-fXI antibodies and methods of use |
CN102600471A (zh) * | 2012-02-15 | 2012-07-25 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种败血症治疗的靶点 |
AU2013258043B2 (en) * | 2012-05-10 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor XI and/or its activated form factor XIa and uses thereof |
WO2014089493A1 (en) | 2012-12-07 | 2014-06-12 | Vanderbilt University | Antibodies against factor xii and uses thereof |
US11390687B2 (en) | 2015-01-02 | 2022-07-19 | Takeda Pharmaceutical Company Limited | Bispecific antibodies against plasma kallikrein and Factor XII |
JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
US11066481B2 (en) * | 2015-07-23 | 2021-07-20 | The Regents Of The University Of California | Antibodies to coagulation factor XIa and uses thereof |
WO2017127468A1 (en) * | 2016-01-22 | 2017-07-27 | Merck Sharp & Dohme Corp. | Anti-coagulation factor xi antibodies |
JP7028471B2 (ja) * | 2016-03-23 | 2022-03-02 | プロティックス ビーヴイ | 第xi因子の活性部位に対するモノクローナル抗体及びその使用 |
TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
JP7022081B2 (ja) * | 2016-06-14 | 2022-02-17 | メルク・シャープ・アンド・ドーム・コーポレーション | 抗凝固因子xi抗体 |
JP2019537451A (ja) | 2016-09-20 | 2019-12-26 | バイエル ファーマ アクチエンゲゼルシャフト | 第xi因子に対する新規抗体およびその用途 |
CA3048156A1 (en) * | 2016-12-23 | 2018-06-28 | Novartis Ag | Factor xi antibodies and methods of use |
US20200231701A1 (en) * | 2016-12-23 | 2020-07-23 | Novartis Ag | Methods of treatment with anti-factor xi/xia antibodies |
CN108409863B (zh) * | 2017-02-10 | 2023-09-26 | 上海仁会生物制药股份有限公司 | 抗凝血因子xi抗体 |
US11958911B2 (en) * | 2017-02-10 | 2024-04-16 | Shanghai Benemae Pharmaceutical | Anti-coagulation factor XI antibody |
CA3083210A1 (en) | 2017-11-22 | 2018-11-20 | Novartis Ag | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
CN113227150B (zh) * | 2018-08-09 | 2023-07-28 | 上海仁会生物制药股份有限公司 | 抗凝血因子xi抗体 |
WO2020154234A1 (en) * | 2019-01-21 | 2020-07-30 | Aronora Inc. | Novel humanized antibodies against factor xi having anti-thrombotic and anti-inflammatory effects and uses thereof |
JP2022528595A (ja) | 2019-04-16 | 2022-06-15 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | 抗FXI/FXIa抗体及びその使用 |
JP2023106635A (ja) | 2020-04-17 | 2023-08-02 | 中外製薬株式会社 | 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法 |
CN114269790B (zh) * | 2020-07-02 | 2023-11-24 | 北京拓界生物医药科技有限公司 | 抗FXI/FXIa抗体、其抗原结合片段及医药用途 |
KR20230035079A (ko) * | 2020-07-03 | 2023-03-10 | 수조우 알파맵 씨오., 엘티디. | 응고인자 xi(fxi) 결합 단백질 |
MX2024004849A (es) | 2021-10-22 | 2024-05-06 | Regeneron Pharma | Anticuerpos de union al dominio a2 del factor xi y metodos para usarlos. |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030235587A1 (en) * | 1998-08-07 | 2003-12-25 | Feuerstein Giora Z. | Anticoagulant agents useful in treatment of thrombosis |
GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
WO2000007626A1 (en) * | 1998-08-07 | 2000-02-17 | Smithkline Beecham Corporation | Use of anti-coagulation factor antibodies as long-lasting protective agents |
US7270976B2 (en) * | 2004-07-19 | 2007-09-18 | American Diagnostica, Inc. | Methods for measuring ADAMTS13 activity and protein on platelets and in plasma |
US20080138837A1 (en) * | 2004-07-19 | 2008-06-12 | Robert Greenfield | Methods and kits for detecting and measuring ADAMTS13/FXI complexes |
WO2009046274A1 (en) * | 2007-10-03 | 2009-04-09 | The University Of Vermont And State Agriculture College | Methods of detection of factor xia and tissue factor |
LT3002298T (lt) * | 2007-11-21 | 2019-12-10 | Univ Oregon Health & Science | Monokloniniai antikūnai prieš faktorių xi ir jų panaudojimo būdai |
WO2009154461A1 (en) | 2008-06-19 | 2009-12-23 | Prothix Bv | Use of anti-factors xi antibodies for prevention of thrombus formation |
EP2373317B1 (en) | 2008-11-25 | 2016-12-14 | Merck Sharp & Dohme Corp. | 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases |
AU2009335643B2 (en) * | 2008-12-18 | 2014-05-29 | Oregon Health & Science University | Anti-fXI antibodies and methods of use |
EA023254B1 (ru) | 2010-05-27 | 2016-05-31 | Мерк Шарп Энд Домэ Корп. | Активаторы растворимой гуанилатциклазы |
WO2011161099A1 (de) | 2010-06-25 | 2011-12-29 | Bayer Pharma Aktiengesellschaft | Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen |
EA201390060A1 (ru) | 2010-07-09 | 2013-07-30 | Байер Интеллектуэль Проперти Гмбх | Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
US9090610B2 (en) | 2011-04-21 | 2015-07-28 | Bayer Intellectual Property Gmbh | Fluoroalkyl-substituted pyrazolopyridines and use thereof |
JP5976788B2 (ja) | 2011-05-06 | 2016-08-24 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換イミダゾピリジンおよびイミダゾピリダジンならびにそれらの使用 |
BR112014004569A2 (pt) | 2011-09-01 | 2017-06-13 | F. Hoffmann-La Roche Ag | composto da fórmula i, métodos para tratar condição inflamatória, artrite reumatoide, asma e distúrbio imune, composição farmacêutica e uso do composto |
MX348470B (es) | 2011-09-02 | 2017-06-13 | Bayer Ip Gmbh | Pirimidinas anilladas sustituidas y uso de las mismas. |
AU2013258043B2 (en) | 2012-05-10 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor XI and/or its activated form factor XIa and uses thereof |
-
2009
- 2009-12-18 AU AU2009335643A patent/AU2009335643B2/en active Active
- 2009-12-18 US US13/140,115 patent/US8388959B2/en active Active
- 2009-12-18 PL PL09837993T patent/PL2373691T3/pl unknown
- 2009-12-18 DK DK09837993.6T patent/DK2373691T3/en active
- 2009-12-18 PT PT09837993T patent/PT2373691T/pt unknown
- 2009-12-18 TR TR2019/04662T patent/TR201904662T4/tr unknown
- 2009-12-18 HU HUE09837993A patent/HUE042940T2/hu unknown
- 2009-12-18 WO PCT/US2009/068768 patent/WO2010080623A2/en active Application Filing
- 2009-12-18 ES ES09837993T patent/ES2720594T3/es active Active
- 2009-12-18 SI SI200931958T patent/SI2373691T1/sl unknown
- 2009-12-18 LT LTEP09837993.6T patent/LT2373691T/lt unknown
- 2009-12-18 CA CA2747519A patent/CA2747519C/en active Active
- 2009-12-18 EP EP09837993.6A patent/EP2373691B1/en active Active
-
2013
- 2013-01-31 US US13/755,322 patent/US8940883B2/en active Active
-
2014
- 2014-12-12 US US14/568,483 patent/US9637550B2/en active Active
-
2019
- 2019-03-28 HR HRP20190605TT patent/HRP20190605T1/hr unknown
- 2019-04-10 CY CY20191100401T patent/CY1121562T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU2009335643B2 (en) | 2014-05-29 |
PT2373691T (pt) | 2019-05-08 |
HRP20190605T1 (hr) | 2019-05-31 |
US20150093395A1 (en) | 2015-04-02 |
AU2009335643A1 (en) | 2011-07-07 |
EP2373691B1 (en) | 2019-01-23 |
CA2747519A1 (en) | 2010-07-15 |
DK2373691T3 (en) | 2019-04-15 |
WO2010080623A3 (en) | 2010-11-18 |
SI2373691T1 (sl) | 2019-05-31 |
US20130129745A1 (en) | 2013-05-23 |
TR201904662T4 (tr) | 2019-05-21 |
US8940883B2 (en) | 2015-01-27 |
ES2720594T3 (es) | 2019-07-23 |
WO2010080623A2 (en) | 2010-07-15 |
HUE042940T2 (hu) | 2019-07-29 |
US9637550B2 (en) | 2017-05-02 |
US8388959B2 (en) | 2013-03-05 |
EP2373691A4 (en) | 2012-10-31 |
CA2747519C (en) | 2019-04-02 |
CY1121562T1 (el) | 2020-05-29 |
EP2373691A2 (en) | 2011-10-12 |
US20110250207A1 (en) | 2011-10-13 |
LT2373691T (lt) | 2019-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL248723A0 (en) | Specific antibodies against the bcr complex and methods of using them | |
LT2373691T (lt) | Anti-fxi antikūnai ir jų panaudojimo būdai | |
IL211623A0 (en) | Anti-notch2 antibodies and methods of use | |
EP2427479A4 (en) | ANTIBODIES AND METHODS OF USE THEREOF | |
ZA201005351B (en) | Anti-cd79b antibodies and immunoconjugates and methods of use | |
EG27167A (en) | Microemulsifiers and methods of making and using same | |
HK1171236A1 (en) | Anti-fcrh5 antibodies and immunoconjugates and methods of use fcrh5 | |
IL215795A0 (en) | Anti-il-17f antibodies and methods of use thereof | |
EP2347038A4 (en) | METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES | |
HK1172896A1 (zh) | 化合物和使用方法 | |
HK1161094A1 (en) | Compounds and methods of use | |
ZA201107128B (en) | Anti-fcrh5 antibodies and immunoconjugates and methods of use | |
IL214433A0 (en) | Anti-fgfr3 antibodies and methods using same | |
HK1149933A1 (en) | Diazacarbazoles and methods of use | |
EP2185719A4 (en) | RANTES ANTIBODIES AND METHOD FOR THEIR USE | |
IL209548A0 (en) | Diazacarbazoles and methods of use | |
EP2388320A4 (en) | ANTI-HS6ST2 ANTIBODIES AND USE THEREOF |